[{"address1": "Life Science and Technology Park", "address2": "1951 NW 7th Avenue Suite 520", "city": "Miami", "state": "FL", "zip": "33136", "country": "United States", "phone": "305 909 0840", "website": "https://longeveron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.", "fullTimeEmployees": 23, "maxAge": 86400, "priceHint": 4, "previousClose": 2.45, "open": 2.39, "dayLow": 2.15, "dayHigh": 2.44, "regularMarketPreviousClose": 2.45, "regularMarketOpen": 2.39, "regularMarketDayLow": 2.15, "regularMarketDayHigh": 2.44, "beta": 0.31, "forwardPE": -0.82397, "volume": 1644139, "regularMarketVolume": 1644139, "averageVolume": 8582690, "averageVolume10days": 39123130, "averageDailyVolume10Day": 39123130, "bid": 2.2, "ask": 2.23, "bidSize": 700, "askSize": 1000, "marketCap": 17698252, "fiftyTwoWeekLow": 0.771, "fiftyTwoWeekHigh": 37.8, "priceToSalesTrailing12Months": 18.096373, "fiftyDayAverage": 1.6508, "twoHundredDayAverage": 10.6157, "currency": "USD", "enterpriseValue": 13571973, "floatShares": 3876470, "sharesOutstanding": 6560660, "sharesShort": 46627, "sharesShortPriorMonth": 91076, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0073, "heldPercentInsiders": 0.12202, "heldPercentInstitutions": 0.01023, "shortRatio": 0.01, "shortPercentOfFloat": 0.0098, "impliedSharesOutstanding": 8044660, "bookValue": 1.208, "priceToBook": 1.8211921, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -21622000, "trailingEps": -9.6, "forwardEps": -2.67, "lastSplitFactor": "1:10", "lastSplitDate": 1711497600, "enterpriseToRevenue": 13.877, "enterpriseToEbitda": -0.699, "52WeekChange": -0.93907505, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "LGVN", "underlyingSymbol": "LGVN", "shortName": "Longeveron Inc.", "longName": "Longeveron Inc.", "firstTradeDateEpochUtc": 1613140200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0810e7c7-ed9c-3408-947e-be0c34d084bb", "messageBoardId": "finmb_410711455", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.2, "targetHighPrice": 15.0, "targetLowPrice": 9.9, "targetMeanPrice": 12.3, "targetMedianPrice": 12.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 2291000, "totalCashPerShare": 0.361, "ebitda": -19420000, "totalDebt": 1896000, "quickRatio": 0.466, "currentRatio": 0.71, "totalRevenue": 978000, "debtToEquity": 62.348, "revenuePerShare": 0.43, "returnOnAssets": -0.8086, "returnOnEquity": -2.15135, "freeCashflow": -9100500, "operatingCashflow": -16240000, "revenueGrowth": 0.964, "grossMargins": 0.48466, "operatingMargins": -7.4634995, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]